A Congressional committee recently began an inquiry into the marketing and regulation of widely used anemia drugs that have raised safety concerns. The anemia drugs may cause patients to suffer complications and die earlier. The House has sent letters to the drugs’ marketers, requesting information about what they knew of the possible risks and their promotional methods. The letters also request the pharmaceutical companies to suspend any consumer advertising or incentive programs for doctors until the FDA has time to determine whether further safety precautions are necessary.
For the full article.